Shots:

• Sanofi to acquire all outstanding shares of Translate Bio for $38.00/share in cash making a total equity value of ~$3.2B with a premium of 30.4% to Translate Bio's one day prior closing price of $29.15. The acquisition is expected to complete in the Q3’21
• The acquisition will utilize mRNA technology to further accelerates Sanofi’s licensed programs to develop transformative therapies & vaccines
• In Jun’18- Sanofi entered into a license agreement with Translate Bio to develop mRNA vaccines & further expanded in 2020 for infectious diseases. Additionally- the recent acquisition of Tidal has expanded Sanofi’s mRNA research capabilities in both immuno-oncology and inflammatory diseases

 to   | Ref: GlobeNewswire | Image: Medcity News